Superaugmented eccentric distance sum connectivity indices: Novel highly discriminating topological descriptors for QSAR/QSPR

Chemical Biology and Drug Design

Volumn 79, Issue 1, 2012, Pages 38-52

  Gupta, Monika ^a   Gupta, Sunil ^b   Dureja, Harish ^a   Madan, Anil Kumar ^c  

^a MAHARSHI DAYANAND UNIVERSITY   (India)

^b J C D College of Pharmacy   (India)

^c PT B D SHARMA UNIVERSITY OF HEALTH SCIENCES   (India)

Author keywords

2 arylbenzimidazole; Checkpoint kinase inhibitors; Superaugmented eccentric distance sum connectivity topochemical indices; Topological indices

Indexed keywords

BENZIMIDAZOLE DERIVATIVE;

ARTICLE; COMBINATORIAL LIBRARY; COMPUTER PROGRAM; DECISION TREE; DRUG DESIGN; HUMAN; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; RANDOM FOREST;

ALGORITHMS; BENZIMIDAZOLES; ENZYME ACTIVATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84155164224     PISSN: 17470277     EISSN: 17470285     Source Type: Journal    
DOI: 10.1111/j.1747-0285.2011.01264.x     Document Type: Article

References (90)

1. Estrada E., Uriarte E. (2001) Recent advances on the role of topological indices in drug discovery research. Curr Med Chem;8:1573-1588.
2. Hann M., Green R. (1999) Chemoinformatics - a new name for an old problem? Curr Opin Chem Biol;3:379-383.
3. Estrada E., Patlewicz G., Uriarte E. (2003) From molecular graphs to drugs. A review on the use of topological indices in drug design and discovery. Ind J Chem;42A:1315-1329.
4. Venkatesh S., Lipper R.A. (2000) Role of the development scientist in compound lead selection and optimization. J Pharm Sci;89:145-154.
5. Hansch C. (1969) A quantitative approach to biochemical structure-activity relationships. Acc Chem Res;2:232-239.
6. Greener M. (2005) QSAR: prediction beyond the fourth dimension. Drug Disc Dev;8:44-47.
7. Waterbeemd V.D., Carter R.E., Grassy G., Kubinyi H., Martin Y.C., Tute M.S., Willett P. (1997) Glossary of terms used in computational drug design. Pure Appl Chem;69:1137-1152.
8. Randic M. (1997) On characterization of chemical structure. J Chem Inf Comput Sci;37:672-687.
9. Katritzky A.R., Gordeeva E.V. (1993) Traditional topological indices vs electronic, geometrical, and combined molecular descriptors in QSAR/QSPR research. J Chem Inf Comput Sci;33:835-857.
10. Devillers J., Balaban A.T. (1999) Topological Indices and Related Descriptors in QSAR and QSPR. Singapore: Gordon and Breach Science Publishers.
11. Ponce Y.M. (2004) Total and local (atom and atom type) molecular quadratic indices: significance interpretation, comparison to other molecular descriptors, and QSPR/QSAR applications. Bioorg Med Chem;12:6351-6369.
12. Basak S.C., Grunwald G.D. (1994) Molecular similarity and risk assessment: analog selection and property estimation using graph invariants. SAR QSAR Environ Res;2:289-307.
13. Basak S.C., Bertelsen S., Grunwald G.D. (1994) Application of graph theoretical parameters in quantifying molecular similarity and structure-activity relationships. J Chem Inf Comput Sci;34:270-276.
14. Hu Q.N., Liang Y.Z., Fang K.T. (2003) The matrix expression, topological index and atomic attribute of molecular topological structure. J Data Sci;1:361-389.
15. Bagchi M.C., Maiti B.C., Bose S. (2004) QSAR of anti tuberculosis drugs of INH type using graphical invariants. J Mol Str (Theochem);679:179-186.
16. Massague J. (2004) G1 cell-cycle control and cancer. Nature;432:298-306.
17. Perona R., Amor V.M., Pinilla R.M., Injesta C.B. (2008) Role of CHK2 in cancer development. Clin Transl Oncol;10:538-542.
18. Kawabe T. (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther;3:513-519.
19. Kastan M.B., Bartek J. (2004) Cell-cycle checkpoints and cancer. Nature;18:316-323.
20. Hoeijmakers J.H. (2001) Genome maintenance mechanisms for preventing cancer. Nature;411:366-374.
21. Bartek J., Lukas J. (2001) Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol;13:738-747.
22. Zhou B.-B.S., Elledge S.J. (2000) The DNA damage response: putting check points in perspective. Nature;408:433-439.
23. Elledge S.J. (1996) Cell cycle checkpoints: preventing an identity crisis. Science;274:1664-1672.
24. Brown E.J., Baltimore D. (2000) ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev;14:397-402.
25. De Klein A., Muijtjens M., Os R.V., Vehoeven Y., Smit B., Carr A.M., Lehmann A.R., Hoeijmakers J.H.J. (2000) Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol;10:479-482.
26. Liu Q., Guntuku S., Cui X.S., Matsuoka S., Cortez D., Tamai K., Luo G., Rivera S.C., Demayo F., Bradley A., Donehower L.A., Elledge S.J. (2000) Chk1 is an essential kinase that is regulated by ATR and required for the G (2)/M DNA damage checkpoint. Genes Dev;14:1448-1459.
27. Takai H., Tominaga K., Motoyama N., Minamishima Y.A., Nagahama H., Tsukiyama T., Ikeda K., Nakayama K., Nakanishi M., Nakayama K.I. (2000) Aberrant cell cycle checkpoint function and early embryonic death in Chk1 (-/-) mice. Genes Dev;14:1439-1447.
28. Zhou B.B., Anderson H.J., Roberge M. (2003) Models of anti-cancer therapy targeting DNA checkpoint kinases in cancer therapy. Cancer Biol Ther;2:S16-S22.
29. Skladanowski A., Bozko P., Sabisz M. (2009) DNA structure and integrity checkpoints during the cell cycle and their role in drug targeting and sensitivity of tumor cells to anticancer treatment. Chem Rev;109:2951-2973.
30. Shiloh Y. (2003) ATM and related protein kinases: safeguarding genome integrity. Nat Rev Cancer;3:155-168.
31. Kastan M.B., Lim D. (2000) The many substrates and functions of ATM. Nat Rev Mol Cell Biol;1:179-186.
32. Bartek J., Lukas J. (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell;3:421-429.
33. Stracker T.H., Usuia T., John Petrini H.J. (2009) Taking the time to make important decisions: the checkpoint effector kinases Chk1 and Chk2 and the DNA damage response. DNA Repair;8:1047-1054.
34. Gent V., Hoeijmakers J.H.J., Kannar R. (2001) Chromosomal stability and the DNA double-stranded break connection. Nat Rev Cancer;2:196-206.
35. Khanna K.K., Jackson S.P. (2001) DNA double-strand breaks: signaling, repair and the cancer connection. Nat Genet;27:247-254.
36. Bartkova J., Horejsi Z., Koed K., Kramer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Orntoft T., Lukas J., Bartek J. (2005) DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature;434:864-870.
37. Pommier Y., Sordet O., Rao V.A., Zhang H., Kohn K.W. (2005) Targeting Chk2 kinase: molecular interaction maps and therapeutic rationale. Curr Pharm Des;22:2855-2872.
38. Antoni L., Sodha N., Collins I., Garrett M.D. (2007) CHK2 kinase: cancer susceptibility and cancer therapy two sides of the same coin. Nat Rev Cancer;7:925-936.
39. Castedo M., Perfettini J.-L., Roumier T., Andreau K., Yakushijin K., Horne D., Medema R., Kroemer G. (2004) The cell cycle checkpoint kinase Chk2 is a negative regulator of mitotic catastrophe. Oncogene;23:4353-4361.
40. Vakifahmetoglu H., Olsson M., Tamm C., Heidari N., Orrenius S., Zhivotovsky B. (2008) DNA damage induces two distinct modes of cell death in ovarian carcinomas. Cell Death Differ;15:555-566.
41. Chabalier-Taste C., Racca C., Dozier C., Larminat F. (2008) BRCA1 is regulated by Chk2 in response to spindle damage. Biochim Biophys Acta;1783:2223-2233.
42. Komarov P.G., Komarova E.A., Kondratov R.V., Christov-Tselkov K., Coon J.S., Chernov M.V., Gudkov A.V. (1999) A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science;285:1733-1737.
43. Evan G., vousden K.H. (2001) Proliferation, cell cycle and apoptosis in cancer. Nature;411:342-348.
44. Hirao A., Kong Y.Y., Mastsuoka S., Wakeham A., Ruland J., Yoshida H., Liu D., Elledge S.J., Mak T.W. (2000) DNA damage-induced activation of p53 by the checkpoint kinase Chk2. Science;287:1824-1827.
45. Takai H., Naka K., Okada Y., Watanabe M., Harada N., Saito S., Anderson C.W., Appella E., Nakanishi M., Suzuki H., Nagashima K., Sawa H., Ikeda K., Motoyama N. (2002) Chk2-deficient mice exhibit radioresistance and defective p53-mediated transcription. EMBO J;21:5195-5205.
46. Jack M.T., Woo R.A., Motoyama N., Takai H., Lee P.W.K. (2004) DNA-dependent protein kinase and checkpoint kinase 2 synergistically activate a latent population of p53 upon DNA damage. J Biol Chem;279:15269-15273.
47. Zhou B.B., Bartek J. (2004) Targeting the checkpoint kinases: chemosensitization versus chemoprotection. Nat Rev Cancer;4:216-225.
48. Arienti K.L., Brunmark A., Axe F.U., McClur K., Lee A., Belvitt J., Neff D.F., Haung L., Crawford S., Pandit C.R., Karlsson L., Breitenbcher J.G. (2005) Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem;48:1873-1885.
49. Jobson A.G., Cardellina J.H. II, Scudiero D., Kondapaka S., Zhang H., Kim H., Shoemaker R., Pommier Y. (2007) Identification of a bis-guanylhydrazone [4, 4--diacetyldiphenylurea-bis(guanylhydrazone); NSC 109555] as a novel chemotype for inhibition of Chk2 kinase. Mol Pharmacol;72:876-884.
50. Carlessi L., Buscemi G., Larson G., Hong Z., Wu J.Z., Delia D. (2007) Biochemical and cellular characterization of VRX0466617, a novel and selective inhibitor for the checkpoint kinase Chk2. Mol Cancer Ther;6:935-944.
51. Larson G., Yan S., Chen H., Rong F., Hong Z., Wu J.Z. (2007) Identification of novel, selective and potent Chk2 inhibitors. Bioorg Med Chem Lett;17:172-175.
52. Jobson A.G., Lountos G.T., Lorenzi P.L., Llamas J., Connelly J., Cerna D., Tropea J.E. et al. (2009) Cellular inhibition of checkpoint kinase 2 (Chk2) and potentiation of camptothecins radiation by the novel Chk2 inhibitor PV1019 [7-Nitro-1H-indole-2-carboxylic acid {4-[1-(guanidinohydrazone)-ethyl]-phenyl}-amide]. J Pharmacol Exp Ther;331:816-826.
53. Zabludoff S.D., Deng C., Grondine M.R., Sheehy A.M., Ashwell S., Caleb B.L., Green S. et al. (2008) AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiats DNA-targeted therapies. Mol Cancer Ther;7:2955-2966.
54. Curman D., Cinel B., Williams D.E., Rundle N., Blockaaron W.D., Goodarzi A., Hutchinsi J.R., Clarkei P.R., Zhou B.-B., Lees-Miller S.P., Andersen R.J., Roberge M. (2001) Inhibition of the G2 DNA damage checkpoint and of protein kinases Chk1 and Chk2 by the marine sponge alkaloid debromohymenialdisine. J Biol Chem;276:17914-17919.
55. Yu Q., Rose J.L., Zhang H., Takemura H., Kohn K.W., Pommier Y. (2002) UCN-01 inhibits p53 up-regulation and abrogates radiation-induced G2-M checkpoint independently of p53 by targeting both of the checkpoint kinases, Chk2 and Chk1. Cancer Res;62:5743-5748.
56. Singh S.V., Antosiewicz A.H., Singh A.V., Lew K.L., Srivastava S.K., Kamath R., Brown K.D., Zhang L., Baskaran R. (2004) Sulforaphane-induced G2/M phase cell cycle arrest involves checkpoint kinase 2-mediated phosphorylation of cell division cycle. J Biol Chem;279:25813-25822.
57. Bucher N., Britten C.D. (2008) G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer;98:523-528.
58. Janetka J.W., Ashwell S. (2009) Checkpoint kinase inhibitors: a review of the patent literature. Expert Opin Ther Pat;19:165-197.
59. Goel A., Madan A.K. (1995) Structure-activity study on anti-inflammatory pyrazole carboxylic acid hydarzide anlogs using molecular connectivity indices. J Chem Inf Comput Sci;35:510-514.
60. Dureja H., Madan A.K. (2005) Topochemical models for prediction of cyclin-dependent kinase 2 inhibitory activity of indole-2-ones. J Mol Mod;11:525-531.
61. Gupta S., Singh M., Madan A.K. (2003) Novel topochemical descriptors for predicting anti-HIV activity. Indian J Chem;42A:1414-1425.
62. Bajaj S. (2005) Study on topochemical descriptors for the prediction of physicochemical and biological properties of molecules. Ph.D. Thesis, New Delhi, India: Guru Gobind Singh Indraprastha University.
63. Bajaj S., Sambhi S.S., Madan A.K. (2004) Prediction of carbonic anhydrase activation by tri-/tetrasubstituted pyridinium-azole drugs: a computational approach using novel topochemical descriptor. QSAR Comb Sci;23:506-514.
64. Kumar V., Sardana S., Madan A.K. (2004) Predicting anti-HIV activity of 2, 3-diaryl-1, 3-thiazolidin-4-ones: computational approach using reformed eccentric connectivity index. J Mol Mod;10:399-407.
65. Gupta S. (2002) Application and development of graph invariants of drug design. Ph.D. Thesis, Patiala, India: Punjabi University.
66. Bajaj S., Sambhi S.S., Madan A.K. (2005) Prediction of anti-inflammatory activity of N-arylanthranilic acids: computational approach using refined Zagreb indices. Croat Chem Acta;78:165-174.
67. Bajaj S., Sambhi S.S., Madan A.K. (2004) Predicting anti-HIV activity of phenethylthiazolethiourea (PETT) analogs:computational approach using Wiener's topochemical index. J Mol Str (Theochem);684:197-203.
68. Dureja H., Gupta S., Madan A.K. (2008) Predicting anti-HIV-1 activity of 6-arylbenzonitriles: computational approach using superaugmented eccentric connectivity topochemical indices. J Mol Graph and Mod;26:1020-1029.
69. Randic M. (1975) On characterization of molecular branching. J Am Chem Soc;97:6609-6615.
70. Gupta S., Singh M., Madan A.K. (2001) Predicting anti-HIV activity: computational approach using a novel topological descriptor. J Comput Aided Mol Des;15:671-678.
71. Bajaj S., Sambi S.S., Madan A.K. (2006) Model for prediction of anti-HIV activity of 2-pyridinone derivatives using novel topological descriptor. QSAR Comb Sci;25:813-823.
72. Sharma V., Goswami R., Madan A.K. (1997) Eccentric connectivity index: a novel highly discriminating topological descriptor for structure - property and structure - activity studies. J Chem Inf Comput Sci;37:273-282.
73. Gupta S., Singh M., Madan A.K. (2000) Connective eccentric index: a novel topological descriptor for predicting biological activity. J Mol Graph Mod;18:18-25.
74. Gutman I., Ruscic B., Trinajstic N., Wicox C.F. (1975) Graph theory and molecular orbitals XII acyclc polyenes. J Chem Phys;62:3399-3405.
75. Gutman I., Randic M. (1977) Algebric characterization of skeletal branching. Chem Phys Lett;47:15-19.
76. Wiener H. (1947) Structural determination of paraffin boiling points. J Am Chem Soc;69:17-20.
77. Kim H., Koehler G.J. (1995) Theory and practice of decision tree induction. Omega Int J Mgmt Sci;23:637-652.
78. Sprogar M., Kokol P., Zorman M., Podgorelec V., Yamamoto R., Masuda G., Sakamoto N. (2001) Supporting medical decisions with vector decision trees. Medinfo;10:552-556.
79. Breiman L. (2001) Random forests. Mach Learn;45:5-32.
80. Dureja H., Gupta S., Madan A.K. (2008) Topological models for the prediction of pharmacokinetic parametes of Cephalosporins using random forest, decision tree and moving average analysis. Sci Pharm;76:401-408.
81. Han L., Wang Y., Bryant S.H. (2008) Developing and validating predictive decision tree models from mining chemical structural fingerprints and high throughput screening data in Pubchem. BMC Bioinformatics;9:401.
82. Bailey D.S., Dean P.M. (1992) Pharmacogenomics and its impact on drug design and optimization. Annu Rev Med Chem;34:339-348.
83. Gallop M.A., Barrett R.W., Dower W.J., Fodor S.P.A., Gordon E.M. (1994) Applications of combinatorial technologies to drug discovery. 1. Background and peptide combinatorial libraries. J Med Chem;37:1233-1251.
84. Gordon E.M., Barrett R., Dower W.J., Fodor S.P.A., Gallop M.A. (1994) Applications of combinatorial technologies to drug discovery. 2. Combinatorial organic synthesis, library screening strategies, and future directions. J Med Chem;37:1386-1401.
85. Devlin J.P. (2000) High Throughput Screening. New York: Marcel Dekker.
86. Estrada E., Molina E. (2001) Novel local (fragment-based) topological molecular descriptors for QSPR/QSAR and molecular design. J Mol Graph Mod;20:54-64.
87. Galvez J., Garcia-Domenech R., Julian-Ortiz J.V., Soler R. (1995) Topological approach to drug design. J Chem Inf Comput Sci;35:272-284.
88. Ivanciuc O., Ivanciuc T., Klein D.J., Seitz W.A., Balaban A.T. (2001) Wiener index extension by counting even/odd graph distances. J Chem Inf Comput Sci;41:536-549.
89. Madan A.K., Dureja H. (2010) Eccentricity based descriptors for QSAR/QSPR, mathematical chemistry monographs, no. 9. In: Gutman I., Furtula B., editors. Novel Molecular Structure Descriptors - Theory and Applications II. Serbia: Croatian Chemical Society; p. 91-138.
90. Nikolic S., Kovacevic G., Milicevic A., Trinajstic N. (2003) The Zagreb indices 30years after. Croat Chem Acta;76:113-124.